New York 2025-2026 Regular Session

New York Senate Bill S06352

Introduced
3/11/25  
Refer
3/11/25  

Caption

Includes nurse practitioners as a provider of services for purposes of collaborative drug therapy management; makes the authorization for pharmacists to perform such management permanent.

Summary

Bill S06352 amends the education law to include nurse practitioners as providers of services for collaborative drug therapy management. This legislation aims to enhance the collaborative role of pharmacists in managing drug therapies alongside physicians and nurse practitioners, allowing for a more integrated approach to patient care. The bill also seeks to make the authorization for pharmacists to perform collaborative drug therapy management permanent, which was previously set to expire in 2026. The collaborative drug therapy management will require written agreements between pharmacists and the healthcare providers involved, ensuring that patient care remains coordinated and that patients are fully informed and consenting to their treatment plans.

Impact

If enacted, this bill will significantly alter the landscape of drug therapy management in New York State by formalizing the role of nurse practitioners in collaborative practices with pharmacists. It will also ensure that the collaborative drug therapy management framework remains in place indefinitely, thus providing stability and clarity for healthcare providers and patients alike. The bill may lead to improved patient outcomes through better medication management, as it allows for a broader range of healthcare professionals to participate in the therapeutic process.

Sentiment

The general sentiment surrounding Bill S06352 appears to be positive, as it promotes collaboration among healthcare providers and aims to improve patient care. However, there may be concerns regarding the implications of expanding the roles of pharmacists and nurse practitioners, particularly in terms of ensuring quality control and maintaining clear lines of responsibility in patient care.

Contention

Notable points of contention may arise from traditionalists within the medical community who may be wary of expanding the scope of practice for pharmacists and nurse practitioners. There may be concerns about the adequacy of training and experience required for pharmacists to manage drug therapies effectively. Additionally, some may argue about the potential for confusion regarding the roles and responsibilities of each healthcare provider involved in collaborative drug therapy management.

Companion Bills

NY A01321

Same As Includes nurse practitioners as a provider of services for purposes of collaborative drug therapy management; makes the authorization for pharmacists to perform such management permanent.

Previously Filed As

NY S04043

Includes nurse practitioners as a provider of services for purposes of collaborative drug therapy management; makes the authorization for pharmacists to perform such management permanent.

NY A01321

Includes nurse practitioners as a provider of services for purposes of collaborative drug therapy management; makes the authorization for pharmacists to perform such management permanent.

NY A11334

Expands collaborative drug therapy management by pharmacists

VA HB1582

Pharmacists; collaborative agreements, drug therapy.

MA H2372

Relative to collaborative drug therapy management optimization

VA HB232

Collaborative agreements; removes registered nurses from list of practitioners, etc.

NC S357

Pharmacists/Collaborative Practice

RI H7534

Sets conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by the state board of pharmacy.

RI S2888

Sets conditions for pharmacists to prescribe tobacco cessation drug therapies, including education approved by the state board of pharmacy.

MN SF4486

Pharmacists authorization to initiate, prescribe, administer, and dispense certain drugs for the treatment of opioid use disorder

Similar Bills

No similar bills found.